FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)										,						
Name and Address of Reporting Person * Cheong Kwang Soo				2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
	AHN PHA	(First) ARMACEUTICA Y GROVE ROA	LS,	3. Date o		rliest Tra	ınsac	tion (N	Month/I	Day/Yo	ear)	_			e title below)		er (specify below)
,		(Street)		4. If Ame	endn	nent, Dat	e Ori	iginal l	Filed(M	onth/Da	y/Year)					up Filing(Chec	k Applicable Lin	e)
ROCKVI	LLE, MD	20850										-			One Reporting More than One	Person Reporting Person		
(Cit	y)	(State)	(Zip)			Tal	ole I	- Non-	-Deriva	tive S	ecurities	Acquir	ed, Di	isposed	of, or Bene	eficially Own	ied	
1.Title of S (Instr. 3)	Security		2. Transaction Date	2A. Deemed 3. Trans Execution Date, if Code					4. Securities Acquired (A) or Disposed of (D)							7. Nature Ownership of Indirect		
(1110411 5)			(Month/Day/Year)				Instr			Instr. 3, 4 and		Tra	Transaction(s) (Instr. 3 and 4)		Fo	Form:	Beneficial Ownership	
				(Wonth	, Da	y/ 1 car)					(A) or	(,111301	o and +,	l.		or Indirect (I)	
							Со	de	V A	mount		Price					(Instr. 4)	
Common	Stock											3	3,000				D	
Reminder:	Report on a	separate line for eac	h class of securities	benefici	ally	owned d	irectl		-									
															of inform to respon	ation d unless th		474 (9-02)
								fo	orm dis	plays	s a curre	ently va	alid O	МВ со	ntrol num	ber.		
			Table II - I								or Bene		Owne	d				
1. Title of		3. Transaction	3A. Deemed	4.		5. Numl		6. Da	ate Exer	cisabl		7. Title				9. Number o		11. Naturo
Derivative Security	Conversion or Exercise		Execution Date, if any	if Transacti Code					ration D nth/Day)	Underl	Amount of Underlying		Derivative Security	Derivative Securities	Form of	p of Indirec Beneficia
(Instr. 3)				(Instr. 8	nstr. 8) Securit Acquire				• ,			Securities (Instr. 3 and 4)		4)	(Instr. 5)	Beneficially Owned	Derivativ Security:	(Instr. 4)
	Security	1				Following Direct (D) Reported or Indirect) [`									
						(D))				T		Transaction (Instr. 4)					
						(Instr. 3, 4, and 5)							(111511.4)	(IIIsti. 4)				
										_			A o:	Amount or				
								Date Exerc	cisable	Date	iration e	Title		Number				
				Code	V	(A)	(D)							hares				
Stock Options									(1)			Comr	non .					
(right-	\$ 0.5	06/11/2013		Α		60,000			<u>(1)</u>	06/	11/2023	Stoc	- 10	50,000	\$ 0	60,000	D	
to-buy) Stock																		
Options	\$ 0.38								<u>(2)</u>	06/	18/2022	Comr	non	20,000		20,000	D	
(right- to-buy)	\$ 0.38								121	00/	16/2022	Stoc	ck	.0,000		20,000	l D	
Stock																		
Options	\$ 1.25							06/0	06/2013	06/0	06/2021	Comr	non 2	20,000		20,000	D	
(right- to-buy)	ψ 1.23							00,0	.0,2012		00/2021	Stoc	ck [.0,000		20,000		
Stock																		
Options (right-	\$ 1.17							06/1	4/201	06/	14/2020	Comr	non 2	20,000		20,000	D	
to-buy)												5100	J.K					
Stock																		
Options (right-	\$ 1.28							06/0	1/2010	06/0	01/2019	Comr	non ck 2	20,000		20,000	D	
to-buy)																		
Stock Options												Comm	mon					
(right-	\$ 3.24							06/3	0/2009	06/3	30/2018	Stoc	ck 2	20,000		20,000	D	
to-buy)																		
Stock Options	0.1.10							0.615	1/200		11/2015	Comr	non	20,000		20.000	_	
(right-	\$ 1.40							06/1	1/2008	5 06/	11/2017	Stoc	ck 2	:0,000		20,000	D	
to-buy) Stock																		
Options	\$ 1.20							05/0	1/200	7 05 //	01/2016	Comr	non	20,000		20,000	D	
(right-	\$ 1.20							05/0	1/200	103/0	01/2016	Stoc	ck 2	.0,000		20,000	D	

to-buy)							

Reporting Owners

D (1 0 N (41)	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Cheong Kwang Soo C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850	X							

Signatures

Tae Heum Jeong, as attorney-in-fact for Kwang Soo Cheong	06/13/2013		
***Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These options vest and become exercisable in full on June 11, 2014.
- (2) These options vest and become exercisable in full on June 18, 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.